Taken together, it is suggested that the downregulation of DOCK2 and PTPRC in CRC contributes to the escape of tumors from immune surveillance; accordingly, their dysregulation could be involved in resistance to immunotherapy. Here, DOCK2 is linked to colorectal carcinoma.